FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that its partner for ATryn® in Europe, Canada and the Middle East, LEO Pharma A/S, has enrolled the first patient in a Phase II study of the recombinant antithrombin product in the treatment of disseminated intravascular coagulation, or DIC, in association with severe sepsis. Full enrollment of about 200 patients into the Phase II study is planned to take approximately 12 months with results expected to be available in the second half of 2008.
